Copenhagen, Denmark, November 19, 2026
Adcendo ApS, a clinical-stage biotechnology company focused on developing innovative antibody-drug conjugates (ADCs) for cancers with high unmet medical needs, has announced encouraging initial clinical data from its ongoing Phase 1 ADCElerate1 trial evaluating ADCE-D01 in patients with advanced soft tissue sarcoma (STS). The investigational therapy demonstrated promising antitumor activity and a favorable safety profile, with a 30% objective response rate (ORR) and an 85% disease control rate (DCR) among evaluable patients receiving treatment every two weeks. The findings were presented during a late-breaking oral presentation at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), held in Barcelona, Spain, from November 18–20, 2026. ADCE-D01 is a novel, first-in-class antibody-drug conjugate targeting urokinase plasminogen activator receptor-associated protein (uPARAP), a protein expressed in several cancers of mesenchymal origin. The results represent an important clinical development milestone for Adcendo and highlight the potential of targeted protein delivery technologies in treating difficult-to-manage solid tumors.
ADCE-D01 Demonstrates Encouraging Antitumor Activity
The initial efficacy findings from the Phase 1 ADCElerate1 study demonstrated encouraging responses across multiple soft tissue sarcoma subtypes. Among the 27 response-evaluable patients receiving ADCE-D01 on an every-two-week (Q2W) dosing schedule, eight patients achieved partial responses, resulting in an objective response rate of 30%. Of these responses, five were confirmed and three remained unconfirmed at the data cutoff. The disease control rate reached 85% (23 out of 27 patients), indicating that a substantial proportion of participants experienced tumor response or disease stabilization. The evaluated patients represented 12 different soft tissue sarcoma subtypes, demonstrating preliminary antitumor activity across a diverse patient population. The median follow-up period was 3.4 months, while the median duration of response had not yet been reached. Importantly, all observed responses were ongoing at the data cutoff, and 81% of evaluable patients remained on treatment. Researchers also observed a trend toward improved efficacy at higher dose levels. These early findings are particularly relevant because advanced soft tissue sarcoma is a heterogeneous group of rare cancers with limited treatment options, especially after patients have received previous systemic therapies.
Novel uPARAP-Targeting ADC Technology
ADCE-D01 is designed to selectively deliver a potent anticancer payload to uPARAP-expressing tumor cells. The uPARAP protein, also known as Endo180, is an endocytic receptor that is overexpressed in several cancers of mesenchymal origin, including soft tissue sarcoma, osteosarcoma, gastrointestinal stromal tumors (GIST), mesothelioma and glioblastoma. Its expression pattern and ability to undergo rapid internalization make it an attractive target for antibody-drug conjugate development. ADCE-D01 combines a specialized uPARAP-binding antibody with a clinically validated protease-cleavable linker and a potent deruxtecan-based cytotoxic payload. Following binding to uPARAP on cancer cells, the antibody-drug conjugate is designed to undergo internalization, allowing the payload to be released and exert its tumor-killing activity. The antibody component is engineered to avoid interfering with the receptor’s natural interaction with collagen. This targeted delivery strategy aims to improve tumor selectivity while limiting unnecessary exposure of healthy tissues to cytotoxic agents. Preclinical studies previously demonstrated encouraging antitumor activity across several experimental tumor models, supporting the advancement of ADCE-D01 into human clinical evaluation.
Phase 1 Safety Results and Regulatory Milestones
The ADCElerate1 study enrolled 47 adults with advanced soft tissue sarcoma, representing 17 different tumor subtypes. Participants had previously received systemic treatments, including chemotherapy and targeted therapies, with a median of two prior treatment lines. The study initially evaluated weekly dosing before transitioning to an every-two-week schedule based on pharmacokinetic findings. On the Q2W schedule, the most common treatment-related adverse events included nausea (59%), infusion-related reactions (41%), fatigue (38%) and hair loss (35%). Neutropenia was the most frequently reported hematological adverse event, occurring in 31% of patients. Only 10% of patients required dose reductions, and no patients discontinued treatment because of adverse events on the Q2W schedule. Prophylactic granulocyte colony-stimulating factor (G-CSF) was also associated with a lower incidence of severe neutropenia in the reported patient groups. The maximum tolerated dose for the Q2W regimen had not yet been reached. Additionally, no cases of interstitial lung disease, febrile neutropenia or stomatitis were reported. ADCE-D01 has received FDA Fast Track Designation and Orphan Drug Designation for soft tissue sarcoma, supporting its development in this area of significant unmet medical need.
Overall, the initial Phase 1 findings position ADCE-D01 as a promising investigational ADC for advanced soft tissue sarcoma. Adcendo continues recruiting patients in the United States and Europe to further evaluate the therapy’s safety, tolerability and antitumor potential. Further clinical follow-up will be important to confirm the durability of responses and determine the appropriate dose for subsequent development. The findings highlight the growing role of next-generation antibody-drug conjugates in precision oncology and the potential of novel tumor-associated targets to expand treatment opportunities for patients with rare and difficult-to-treat cancers.
Source: Adcendo press release



